GET DAILY SIGNALSSS Innovations International (SSII) Q3 2026 Earnings Preview: Revenue Momentum and Regulatory Updates
Key Takeaways
- SS Innovations International is scheduled to report third-quarter 2026 results for the quarter ended September 30, 2026, with consensus earnings per share (EPS) near -$0.01 and revenue expectations of roughly $14 million to $15 million.
- The company follows a standard calendar fiscal year, so its third quarter covers the July-through-September 2026 period.
- In the prior quarter (Q2 2026), the company posted record revenue of $13.94 million, beating the ~$12 million consensus by about 16%, while EPS of -$0.01 matched estimates.
- Investors are watching SSi Mantra surgical robotic system unit sales, procedure volume, and progress on the U.S. Food and Drug Administration (FDA) 510(k) clearance pathway.
- Analyst coverage remains limited but constructive, with a consensus Strong Buy rating and an average 12-month price target of $7.00.
- For additional context, review the company's Major News, Today's Price Move, Price Targets, and Forecast across dedicated pages.
- Explore Trending AI Robots to discover AI-driven trading strategies and market ideas.
Why the Upcoming Report Matters
SS Innovations International operates as a commercial-stage surgical robotics firm, with its SSi Mantra system positioned as a lower-cost option compared to premium platforms in the space. Revenue expanded by roughly 106% during 2025, and the record $13.94 million in Q2 2026 points to sustained interest, especially across India. The next earnings update will show whether that growth holds. Given ongoing unprofitability, attention centers on operating leverage, system placements, and steps toward U.S. regulatory approval that could open a much bigger market. This release serves as a checkpoint on both revenue trends and the longer-term path to scale.
Consensus Estimates for Q3 2026
Expectations for the third quarter call for EPS around -$0.01, alongside revenue in the $14 million to $15 million range. That would mark solid year-over-year improvement from the $12.83 million in revenue and -$0.02 EPS posted in Q3 2025. The revenue bar sits a bit above the prior quarter's $13.94 million, reflecting hopes for further SSi Mantra placements. Procedure volume, which exceeded 10,500 cumulative cases by late April 2026, will also draw scrutiny, along with any fresh details on the FDA 510(k) process. In early October 2026 the company filed its reply to an FDA request for more information, so regulatory commentary could prove influential.
Market Sentiment Ahead of the Print
Investor mood reflects a blend of optimism around revenue expansion and caution tied to persistent losses plus a share price that has fallen from its 52-week peak. Year-to-date softness highlights concerns over cash usage, potential dilution, and the still-pending U.S. approval timeline. Risks include the pace of FDA clearance, currency and demand shifts in overseas markets, and heavy reliance on India. A revenue beat or positive regulatory update could support the growth story, whereas slower placements or delays might pressure sentiment.
What to Watch After the Release
Management commentary on the U.S. regulatory process will likely take center stage. The 510(k) submission for the SSi Mantra system stands as the largest potential catalyst, since clearance could grant access to a far larger addressable market. Updates on the October 2026 response to the FDA will be parsed closely. Beyond that, geographic expansion and procedure utilization merit attention; approvals in places such as Colombia, Oman, Sri Lanka, and Kenya, plus telesurgery progress in Indonesia and the Philippines, provide context. Rising utilization of the installed base and recurring instrument revenue would signal compounding growth rather than dependence on new system sales alone. Finally, the balance between investment spending and narrowing losses will indicate whether expenses are being managed efficiently as revenue grows and whether cash resources support the route to profitability.
Integrating Tickeron Tools in My Research
I also checked this using Tickeron's AI Screener to see how SSII compares to other names in the healthcare technology space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SSII in -2.94% downward trend, sliding for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SSII declined for three days, in 121 of 131 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for SSII entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SSII's RSI Indicator exited the oversold zone, 20 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for SSII just turned positive on October 27, 2026. Looking at past instances where SSII's MACD turned positive, the stock continued to rise in 29 of 38 cases over the following month. The odds of a continued upward trend are 76%.
Following a +11.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SSII advanced for three days, in 62 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
SSII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.846) is normal, around the industry mean (4.170). P/E Ratio (0.000) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (12.887) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. SSII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SSII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the Dow Jones Industrial Average?
What Role Does Inflation Play in my Retirement Planning?
What are the key distinctions between the Dow Jones Industrial Average and the S&P 500?
AI Trading Bots: Top 10 Day Traders, Signals Only, on October 9, 2024
AAPL, AMZN, LLY, MA, ABNB, MSTR, RBLX, MRNA, RDDT, XYZ | Q1 2025 Earnings Preview: Thursday, May 1, 2025
General Information
Industry MedicalNursingServices
Advertisement